A Case of Acute Lymphoblastic Leukemia Developing After a Diagnosis of Myelodysplastic Syndrome Following Lenalidomide Therapy for Multiple Myeloma
Abstract
Acute lymphoblastic leukemia (ALL) following lenalidomide (LEN) therapy is rare. A 64-year-old man developed myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) six years after LEN maintenance therapy following autologous stem cell transplantation for multiple myeloma, followed by Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (ALL) 14 months later. A genomic analysis at diagnosis revealed PRPF8, XBP1, and BCORL1 mutations with IKZF1 and PAX5 deletions. No abnormalities were detected in the archived samples from the myeloma or MDS phases. He achieved complete molecular remission after chemotherapy. Although clonal continuity could not be demonstrated, a comprehensive genomic analysis provided insights into the complex clonal architecture of the clinical course.
Related
- SECONDARY B-LYMPHOBLASTIC TRANSFORMATION IN A PATIENT WITH MULTIPLE MYELOMA FOLLOWING AUTOLOGOUS TRANSPLANTATION AND LENALIDOMIDE MAINTENANCE: A CASE REPORT
- Case Report: Durable response to lenalidomide rechallenge after azacitidine failure in myelodysplastic neoplasm with del(5q)
- Lenalidomide-associated B-cell acute lymphoblastic leukemia in a multiple myeloma patient: a case report
- Mothers' emotional and caregiving experiences during the first month after a child's acute lymphoblastic leukemia diagnosis: A qualitative study
- Therapy-related T-lymphoblastic lymphoma following acute myeloid leukemia remission with IDH2 mutation persistence
BibTeX
@article{nakamura2026case,
title = {{A Case of Acute Lymphoblastic Leukemia Developing After a Diagnosis of Myelodysplastic Syndrome Following Lenalidomide Therapy for Multiple Myeloma}},
author = {Takayuki Nakamura and Fumihiko Mouri and Yoshimi Maehiro and Yuichiro Semba and Masahiro Umeda and Toshinobu Fukuyama and Yoshitaka Yamasaki and Shuki Oya and Maki Yamaguchi and Takahiro Maeda and Koji Nagafuji},
journal = {Internal Medicine},
year = {2026},
month = sep,
doi = {10.2169/internalmedicine.7929-26},
url = {https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7929-26/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - A Case of Acute Lymphoblastic Leukemia Developing After a Diagnosis of Myelodysplastic Syndrome Following Lenalidomide Therapy for Multiple Myeloma
AU - Takayuki Nakamura
AU - Fumihiko Mouri
AU - Yoshimi Maehiro
AU - Yuichiro Semba
AU - Masahiro Umeda
AU - Toshinobu Fukuyama
AU - Yoshitaka Yamasaki
AU - Shuki Oya
AU - Maki Yamaguchi
AU - Takahiro Maeda
AU - Koji Nagafuji
PY - 2026
DA - 2026/09/22
JO - Internal Medicine
DO - 10.2169/internalmedicine.7929-26
UR - https://www.jstage.jst.go.jp/article/internalmedicine/advpub/0/advpub_7929-26/_article
AB - Acute lymphoblastic leukemia (ALL) following lenalidomide (LEN) therapy is rare. A 64-year-old man developed myelodysplastic syndrome with excess blasts-2 (MDS-EB-2) six years after LEN maintenance therapy following autologous stem cell transplantation for multiple myeloma, followed by Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (ALL) 14 months later. A genomic analysis at diagnosis revealed PRPF8, XBP1, and BCORL1 mutations with IKZF1 and PAX5 deletions. No abnormalities were detected in the archived samples from the myeloma or MDS phases. He achieved complete molecular remission after chemotherapy. Although clonal continuity could not be demonstrated, a comprehensive genomic analysis provided insights into the complex clonal architecture of the clinical course.
SN - 1349-7235
SN - 0918-2918
ER -